Treatment Of Recurrent Ovarian Cancer With Intravenous Chemotherapy And Intraperitoneal Heat Perfusion Chemotherapy

Objective: To analyze the safety and efficacy of intravenous chemotherapy combined with intraperitoneal heat perfusion chemotherapy to treat recurrent ovarian cancer and a reference for treatment of ovarian cancer.Methods:Select 50 cases of patients with recurrent ovarian cancer,in January 2014 to January 2017 in hospital,retrospective analysis to its general information,in accordance with the treatment can be divided into two groups,a group for the research group(25 cases),another group as control group(25 cases).In the control group,25 patients with recurrent ovarian cancer were treated with conventional intravenous chemotherapy,and 25 patients with recurrent ovarian cancer were treated with intravenous chemotherapy and intraperitoneal heat infusion chemotherapy.Compared with two groups of recurrent ovarian cancer,PFS,quality of life improvement,adverse reaction rate and recent treatment were effective.Results:(1)On two groups of patients with recurrent ovarian cancer median PFS with statistical analysis,the analysis results show that 25 patients with recurrent median PFS was 15.06 months,and the control group of25 patients with recurrent ovarian cancer median PFS was 10.59 months,the differences between the two groups was statistically significant(P <0.05).(2)Among the 25 patients with recurrent ovarian cancer,22 patients with recurrent ovarian cancer improved their quality of life and the totalimprovement rate was 88%.In the control group of 25 patients with recurrent ovarian cancer,13 patients with recurrent ovarian cancer had improved quality of life,with a total improvement rate of 52%,and the difference between the two groups was statistically significant(P < 0.05).(3)Control group of 25 cases of recurrent ovarian cancer patients,14 cases with nausea and vomiting,rate of56%,12 patients with recurrent ovarian cancer ?-? mild reaction,2 cases of recurrent ovarian cancer patients to ?-? severe reaction;Team of 25 cases of recurrent ovarian cancer patients,11 cases with nausea and vomiting,rate of 44%,11 patients with recurrent ovarian cancer are ?-level ? mild reaction,there was no statistically significant difference in the two groups(P >0.05).In the control group of 25 patients with recurrent ovarian cancer,16 cases with bone marrow suppression,the incidence was 64%,of which 13 patients with recurrent ovarian cancer to ?-? mild reaction,3 cases of ?-level? severe reaction;Team of 25 cases of recurrent ovarian cancer patients,12 cases with bone marrow suppression,the incidence was 48%,including 10 patients with recurrent ovarian cancer ?-? mild reaction,2 cases of recurrent ovarian cancer ?-? severe reactions,two groups have no difference(P > 0.05).In the control group,there were 25 patients with recurrent ovarian cancer,3 of whom had abnormal liver and kidney function,and the incidence rate was 12%,all of which were mildly abnormal.Of the 25 patients with recurrent ovarian cancer,2 showed abnormal liver and kidney function,and the incidence was 8%,both of which were mildly abnormal,with nodifference between the two groups(P > 0.05).In the control group of 25 patients with recurrent ovarian cancer,2 cases of abdominal pain abdominal distension,the incidence was 8%,mild effects are ?-? level;Team of 25 cases of recurrent ovarian cancer patients,10 cases with abdominal pain,abdominal distension rate of 40%,mild effects are ?-? level;The difference between the two groups was statistically significant(P < 0.05).(4)In the group of 25 patients with recurrent ovarian cancer,1 case of PD,2 SD,15 PR,7 cases CR,the total effective rate(PR+CR)was 88%(22/25),and ineffective(PD+SD)was 12%(3/25).Among the 25 patients with recurrent ovarian cancer in the control group,4 were PD,7 were SD,10 were PR,4 were CR,and the total effective rate(PR+CR)was 56%(14/25)in the recent treatment,and the invalid(PD+SD)was 44%(11/25).Compared with the control group,the total effective rate of recent treatment was higher(P < 0.05).Conclusion:(1)In comparison with conventional intravenous chemotherapy way,intravenous chemotherapy and intraperitoneal hot perfusion chemotherapy joint used in the treatment of recurrent ovarian cancer,in addition to the incidence of abdominal pain abdominal distension has certain promotion,other adverse reactions did not increase,with good tolerance.(2)Intravenous chemotherapy combined with intraperitoneal thermal perfusion chemotherapy in the treatment of recurrent ovarian cancer can improve the quality of patients ovarian cancer and extend the PFS.(3)Compared with conventional venous chemotherapy,intravenous chemotherapy and intraperitoneal fusion chemotherapy are more effective inthe treatment of recurrent ovarian cancer.